Device Trial Radar · NCT06037109
VIDAS® NEPHROCLEAR Reference Interval Study
Last checked: Nov 21, 2026Latest source record: Feb 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
585
Actual
Start
Jul 18, 2023
Primary completion
Dec 28, 2023
Study completion Dec 28, 2023
Sponsor
- Lead sponsor
- BioMérieuxNot on our public-company list
- Sponsor type
- Industry
- First posted
- Sep 14, 2023
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a multi-center sample analysis study in which urine samples previously collected from apparently healthy adult subjects, and subjects with stable chronic morbidities but without AKI in order to establish the reference range for the VIDAS® NEPHROCLEAR™ CCL14 test.
Conditions
- Healthy
Interventions
Diagnostic Test: VIDAS® NEPHROCLEAR™ CCL14 TestDevice
Previously collected urine samples will be tested using the VIDAS® NEPHROCLEAR™ CCL14 Test
Primary outcomes
What the sponsor says the trial is designed to measure.
- CCL14 concentration in urineTime frame: Samples tested within 2 years of collection
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
George Washington University
Washington D.C., District of Columbia
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.